Triple Regulator (TIA-39-C20): 12mg
Weight managementDescription
Tia-39-c20 (triple regulator) is a 39-amino acid triple incretin agonist belonging to the peptide receptor modulator research series. it simultaneously activates three receptors: the glp-1 receptor (glp-1r), the gip receptor (gipr), and the glucagon receptor (gcgr). this triple mechanism adds glucagon receptor activation on top of dual incretin agonism — glucagon signaling directly increases resting energy expenditure and hepatic fat oxidation, producing weight loss effects beyond appetite suppression alone. features a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2381089-83-2. structurally analogous in class to retatrutide. once-weekly subcutaneous injection. key reference literature: jastreboff et al. (nejm 2023) — triple-hormone-receptor agonist phase 2 obesity trial (24.2% weight loss at 48 weeks); sanyal et al. (nature medicine 2024) — retatrutide for masld; rosenstock et al. (lancet 2023) — phase 2 retatrutide vs placebo.
Specifications
| Amount in Vial | 12mg |
|---|---|
| BAC Water | 1.2ml |
| Amount per Unit | 0.1mg per unit |
| Recommended Dose | titrate up from 2mg to 12mg (20 to 120 units) |
| Frequency | 1x per week |
| Injection Type | Subcutaneous |
| Timing | Same Day Every Week / Starting Dose Is 2 MG — Titrate Very Slowly |
Dose Calculator
Based on 0.1mg per unit (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 12mg
Add BAC water: 1.2ml
Concentration: 0.1mg per unit
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.